Awada A - Search Results

1

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Delord JP, et al. Among authors: awada a. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. Target Oncol. 2021. PMID: 33170484 Clinical Trial.

2

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J; EORTC Early Clinical Studies Group. Awada A, et al. Eur J Cancer. 2002 Nov;38(17):2272-8. doi: 10.1016/s0959-8049(02)00379-9. Eur J Cancer. 2002. PMID: 12441264 Clinical Trial.

3

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Strumberg D, et al. Among authors: awada a. J Clin Oncol. 2005 Feb 10;23(5):965-72. doi: 10.1200/JCO.2005.06.124. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613696 Clinical Trial.

4

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M. Awada A, et al. Br J Cancer. 2005 May 23;92(10):1855-61. doi: 10.1038/sj.bjc.6602584. Br J Cancer. 2005. PMID: 15870716 Free PMC article. Clinical Trial.

5

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M. Awada A, et al. Eur J Cancer. 2008 Jan;44(1):84-91. doi: 10.1016/j.ejca.2007.10.003. Epub 2007 Nov 26. Eur J Cancer. 2008. PMID: 18039566 Clinical Trial.

6

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.

Awada A, Piccart MJ, Jones SF, Peck RA, Gil T, Lebwohl D, Wu CY, Burris HA 3rd. Awada A, et al. Cancer Chemother Pharmacol. 2009 Feb;63(3):417-25. doi: 10.1007/s00280-008-0751-5. Epub 2008 Apr 29. Cancer Chemother Pharmacol. 2009. PMID: 18446338 Clinical Trial.

7

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

Dal Lago L, D'Hondt V, Awada A. Dal Lago L, et al. Among authors: awada a. Oncologist. 2008 Aug;13(8):845-58. doi: 10.1634/theoncologist.2007-0233. Epub 2008 Aug 11. Oncologist. 2008. PMID: 18695262 Free article. Review.

8

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A. Awada A, et al. J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209247 Clinical Trial.

9

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Aftimos P, Awada A. Aftimos P, et al. Among authors: awada a. Adv Ther. 2011 Nov;28(11):973-85. doi: 10.1007/s12325-011-0070-9. Epub 2011 Oct 19. Adv Ther. 2011. PMID: 22020735 Review.

10

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G. Schöffski P, et al. Among authors: awada a. Eur J Cancer. 2012 Jan;48(2):179-86. doi: 10.1016/j.ejca.2011.11.001. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119200 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

546 results

Search Page